<DOC>
	<DOCNO>NCT01711463</DOCNO>
	<brief_summary>In study , fluticasone furoate ( FF ) vilanterol ( VI ) different dose combination ( 50/25mcg , 100/25mcg 200/25mcg ) administer single dry powder device evaluate PD , PK , safety tolerability combination healthy Chinese subject . The information gather used support clinical development program fix dose combination FF/VI inhalation powder Chinese population .</brief_summary>
	<brief_title>Relovair PD PK Chinese Healthy Subjects</brief_title>
	<detailed_description>This single centre , double-blind , placebo-controlled , four-way cross , randomize , single repeat dose study . A total 16 healthy subject age 18-45 year randomise aim achieve least 10 evaluable subject treatment period . The primary objective evaluate systemic steroid PD effect ( serum cortisol 24 hour weight mean Day 7 ) FF systemic ß-adrenergic PD effect ( ECG maximum QTcF 0-4h whole blood potassium 0-4h Day 1 Day 7 ) VI ; secondary objective aim evaluate PK , safety tolerability FF/VI inhalation powder single repeat dose administration .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy male female 18 45 year age inclusive . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects blood pressure value outside normal range [ systolic ( 90139 mmHg ) diastolic ( 5089 mmHg ) ] subject ECG finding suggestive previous MI always exclude enrollment . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception completion followup visit . Male subject female partner childbearing potential must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication completion followup visit . Body weight &gt; = 50 kg BMI within range 19 24 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . No significant abnormality 12lead ECG screening , include follow specific requirement : Ventricular rate &gt; = 45 beat per minute ; PR interval &lt; =210msec ; No pathological Q wave ; QRS interval &gt; = 60msec &lt; =120msec ; The waveform must enable QT interval clearly define ; QTc interval must &lt; 450msec ( QTcF ; machine manual reading ) base single ECG value , average three ECGs obtain brief recording period . Subjects current nonsmoker , use tobacco product 12 month period precede screen visit , pack history &lt; =5 pack year . Subjects able use inhalation device satisfactorily . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen admission Unit . A positive urinary cotinine test screen admission Unit . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent 285mL glass full strength beer 425mL schooner light beer 1 ( 30mL ) measure spirit 1 glass ( 100mL ) wine ( NHMRC Guidelines [ NHMRC , 2001 ] ) . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component ( magnesium stearate lactose etc . ) history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History milk protein allergy . History adverse reaction include immediate delay hypersensitivity ICS , β2agonist sympathomimetic drug . Blood donation sample study subject within three month precede first dose study drug blood donation entire study . Pregnant female determine positive urine pregnancy test screen prior dosing . Lactating female . Subjects suffer upper low respiratory tract infection within 4 week screen visit . The subject take oral corticosteroid le 8 week screen visit . The subject take inhaled , intranasal topical steroid le 4 week screen visit . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Fluticasone furoate ( FF )</keyword>
	<keyword>novel dry powder device</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>vilanterol ( VI )</keyword>
	<keyword>Healthy Chinese subject</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>